Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it has completed the previously announced sale of shares of its Series A 3.6% convertible preferred stock pursuant to a registered direct offering representing gross proceeds of approximately $13.5 million. The preferred stock is convertible into shares of Cytori’s common stock at the option of the investors at a conversion price of $0.52. Cytori also issued warrants to purchase an aggregate of 25,961,541 shares of Cytori’s common stock at an exercise price of $0.5771 per share in the offering.

Cytori plans to use the net proceeds from this offering for working capital and general corporate purposes, which include funding its ongoing and future clinical studies.

Roth Capital Partners acted as the lead placement agent for the offering and Maxim Group LLC served as a co-placement agent for the offering.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Cytori, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended.

About Cytori Therapeutics, Inc.

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution® system product family. For more information visit www.cytori.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. Such statements, including, but not limited to, those regarding the Company’s expectations regarding its fundraising efforts, including the anticipated use of proceeds from the offering, involve known and unknown risks that relate to the Company’s future events or future financial performance and the actual results could differ materially from those discussed in this communication. These and other factors are identified and described in more detail in our filings with the SEC, including the prospectus supplement filed with the SEC on October 8, 2014 and the Company’s Form 10-K, Forms 10-Q and its other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.